IL-1 Blockade Reduces Inflammation in Pulmonary Arterial Hypertension and Right Ventricular Failure: A Single-Arm, Open-Label, Phase IB/II Pilot Study

Inclusion criteria included group 1 PAH (7) (not associated with connective tissue disease, human immunodeficiency virus, portal hypertension, or schistosomiasis), age >18 years, and symptomatic RV failure (objective findings of RV dysfunction by echocardiography [RV diastolic diameter >4.3 cm...

Full description

Saved in:
Bibliographic Details
Published in:American journal of respiratory and critical care medicine 2019-02, Vol.199 (3), p.381-384
Main Authors: Trankle, Cory R, Canada, Justin M, Kadariya, Dinesh, Markley, Roshanak, De Chazal, Horacio Medina, Pinson, Janet, Fox, Adam, Van Tassell, Benjamin W, Abbate, Antonio, Grinnan, Daniel
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Correspondence
Cytokines
Drug dosages
FDA approval
Feasibility studies
Female
Heart failure
Heart Failure - complications
Humans
Hypertension, Pulmonary - complications
Inflammation - complications
Inflammation - prevention & control
Interleukin 1 Receptor Antagonist Protein - administration & dosage
Interleukin-1 - antagonists & inhibitors
Male
Middle Aged
Patients
Pilot Projects
Pulmonary Artery
Pulmonary hypertension
Questionnaires
Ventricular Dysfunction, Right - complications
Ventricular Function, Right
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Inclusion criteria included group 1 PAH (7) (not associated with connective tissue disease, human immunodeficiency virus, portal hypertension, or schistosomiasis), age >18 years, and symptomatic RV failure (objective findings of RV dysfunction by echocardiography [RV diastolic diameter >4.3 cm, fractional area change
ISSN:1073-449X
1535-4970
DOI:10.1164/rccm.201809-1631LE